Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.74), $0.07 better than the analyst estimate of ($0.81).

“We are very excited about the recent FDA approval of CAPLYTA™ (lumateperone) for the treatment of schizophrenia and we are fully prepared for our planned commercial launch later this month,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “We have also continued to advance our pipeline programs in 2019 and anticipate a number of meaningful developments in 2020, including reporting topline data from our lumateperone Phase 3 trial in bipolar depression and topline data from our ITI-214 Phase 1/2 trial in heart failure.”

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.